In Europe, more than 23,000 new cases of cervical cancer occur annually. In Spain, the incidence is 10.9 per 100,000 affected women, placing it as the second most common cancer in women aged 15-44 years, after breast cancer.
The HPV vaccines (HPV) administered to 100% of girls would get a significant reduction in the number of cases of cervical cancer, which would become a residual disease. Could expect in the coming years a reduction of 98% of cases. We are currently in Spain with very low rates of vaccination, and missing the opportunity to protect many girls from possible infections arising from HPV.
Where the vaccine is indicated
The vaccine is indicated for all women at risk of becoming infected with HPV, it's a preventive vaccine that prevents infection by the virus. In women with no current partner, women without a stable partner, with more than one partner or whose partners have more than one sexual partner, the vaccine will be indicated. Only they fall outside those monogamous women with stable long-term partner and whose partner is monogamous. Another group of subsidiaries vaccination patients are those undergoing cervical conization, decreasing in this group the chances of recurrence. Before vaccination performing cervical HPV determination is not necessary.
Details of the vaccine
Preventing new HPV infections is the main benefit of the vaccine. There is no age limit at which it is shown that the vaccine is not useful, is only proven efficacy in women under 55 years.
In girls of 12-14 years, the effectiveness is demonstrated if the vaccine is administered in two separate doses by at least six months. As the debate over whether men should be vaccinated, from the collective point of view, it is more attractive to increase the effort in vaccination of women for better vaccination rates before vaccination ask men.